QuidelOrtho Makes Correction To 2024 Guidance To Widen Range For Adj EPS To Align With Adj EBITDA Guidance; Now Sees Adj EPS Of $1.88-$3.60 Vs . February 13 Outlook Of $2.40-$3.07 (Est $3.74)
Portfolio Pulse from Benzinga Newsdesk
QuidelOrtho has revised its 2024 financial guidance, widening the range for adjusted EPS to $1.88-$3.60 from the previously announced $2.40-$3.07. This adjustment is made to align with the adjusted EBITDA guidance, while the midpoint of the adjusted EPS range remains unchanged.
February 16, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
QuidelOrtho revises its 2024 EPS guidance to a wider range of $1.88-$3.60, aligning it with adjusted EBITDA guidance. The midpoint of the EPS range remains the same.
The adjustment in QuidelOrtho's EPS guidance to a wider range may introduce uncertainty among investors, potentially leading to short-term volatility in the stock price. However, since the midpoint of the adjusted EPS range remains unchanged, this indicates that the company's overall financial outlook for 2024 is stable. This stability might mitigate any negative impact from the increased range of the guidance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100